CN118946362A - 医药制剂的灭菌法和包装体 - Google Patents

医药制剂的灭菌法和包装体 Download PDF

Info

Publication number
CN118946362A
CN118946362A CN202380030713.XA CN202380030713A CN118946362A CN 118946362 A CN118946362 A CN 118946362A CN 202380030713 A CN202380030713 A CN 202380030713A CN 118946362 A CN118946362 A CN 118946362A
Authority
CN
China
Prior art keywords
pharmaceutical composition
aqueous pharmaceutical
salt
pyrido
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380030713.XA
Other languages
English (en)
Chinese (zh)
Inventor
远藤洋子
真崎贤治
仙波久实
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of CN118946362A publication Critical patent/CN118946362A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/022—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
CN202380030713.XA 2022-03-30 2023-03-29 医药制剂的灭菌法和包装体 Pending CN118946362A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022056765 2022-03-30
JP2022-056765 2022-03-30
PCT/JP2023/012751 WO2023190653A1 (ja) 2022-03-30 2023-03-29 医薬製剤の滅菌法と包装体

Publications (1)

Publication Number Publication Date
CN118946362A true CN118946362A (zh) 2024-11-12

Family

ID=88202031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380030713.XA Pending CN118946362A (zh) 2022-03-30 2023-03-29 医药制剂的灭菌法和包装体

Country Status (8)

Country Link
US (1) US20250213588A1 (cg-RX-API-DMAC7.html)
EP (1) EP4501329A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023190653A1 (cg-RX-API-DMAC7.html)
KR (1) KR20240165977A (cg-RX-API-DMAC7.html)
CN (1) CN118946362A (cg-RX-API-DMAC7.html)
CA (1) CA3254890A1 (cg-RX-API-DMAC7.html)
TW (1) TW202404607A (cg-RX-API-DMAC7.html)
WO (1) WO2023190653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250214992A1 (en) * 2022-03-30 2025-07-03 Santen Pharmaceutical Co., Ltd. High-purity compound production method and purification method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0318772A (ja) 1989-06-16 1991-01-28 Mitsubishi Cable Ind Ltd 絶縁体の絶緑性能評価方法
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination
EP4178948A2 (en) * 2020-07-29 2023-05-17 Universidade de Santiago de Compostela Functionalized isonitriles and products, preparation and uses thereof
CA3189821A1 (en) * 2020-08-04 2022-02-10 Santen Pharmaceutical Co., Ltd. Agent for treating myopia, preventing myopia and/or suppressing myopia progression
JP7253813B2 (ja) 2020-08-07 2023-04-07 株式会社ユニバーサルエンターテインメント 遊技機
KR20230087514A (ko) * 2020-10-14 2023-06-16 산텐 세이야꾸 가부시키가이샤 안정한 의약 조성물

Also Published As

Publication number Publication date
US20250213588A1 (en) 2025-07-03
JPWO2023190653A1 (cg-RX-API-DMAC7.html) 2023-10-05
KR20240165977A (ko) 2024-11-25
CA3254890A1 (en) 2025-04-09
EP4501329A1 (en) 2025-02-05
EP4501329A4 (en) 2026-03-25
TW202404607A (zh) 2024-02-01
WO2023190653A1 (ja) 2023-10-05

Similar Documents

Publication Publication Date Title
ES2901140T3 (es) Composiciones farmacéuticas de atropina
AU2016326572B2 (en) Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
WO2014057365A1 (en) Stable injectable pharmaceutical composition of epinephrine or salts thereof
JP2025129261A (ja) クロルヘキシジンを含有する医薬組成物
JP7062846B1 (ja) 安定な医薬組成物
US20230135366A1 (en) Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products
TW202404607A (zh) 醫藥製劑之滅菌法與包裝體
JP2019019075A (ja) ペメトレキセド含有液状医薬組成物
JP7378959B2 (ja) 眼科用組成物
JP6653037B2 (ja) 水性液剤
EP2952190B1 (en) Stable aqueous solution
TWI773778B (zh) 含有水溶性黏稠化劑之醫藥組合物
JP6817877B2 (ja) ドルゾラミド、高分子およびホウ酸を含有する医薬組成物
JP2022062596A (ja) エピナスチン又はその塩を含有する花粉破裂抑制剤
EP4512404A1 (en) Composition for ophthalmic use containing sepetaprost
JP7447072B2 (ja) 水性液剤
HK40071854B (en) Pharmaceutical composition
JP2024090829A (ja) 滅菌容器に収容されるエピナスチン含有水性医薬組成物
JP2024052135A (ja) 水性液剤
WO2025079591A1 (ja) セペタプロストを含有する点眼液
JP2025520938A (ja) 注射用フェニレフリン組成物
CN114761022A (zh) 药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination